Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1229-1239

  Louie, Arnold ^a,c   VanScoy, Brian D ^a,c   Brown, David L ^a,c   Kulawy, Robert W ^a,d   Heine, Henry S ^b,c   Drusano, George L ^a,c  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d ICON Development Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; LINEZOLID; MEROPENEM; MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERICIDAL ACTIVITY; BROTH DILUTION; COLONY FORMING UNIT; COMPARATIVE EFFECTIVENESS; DRUG HALF LIFE; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPORE GERMINATION; TREATMENT OUTCOME;

ACETAMIDES; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACILLUS ANTHRACIS; CIPROFLOXACIN; DOXYCYCLINE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, BIOLOGICAL; OXAZOLIDINONES; PREDICTIVE VALUE OF TESTS; QUINOLINES; SPORES, BACTERIAL; THIENAMYCINS; VIRAL LOAD;

EID: 84863405472     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01109-10     Document Type: Article

References (44)

1. Athamna A, et al. 2004. Selection of Bacillus anthracis isolates resistant to antibiotics. J. Antimicrob. Chemother. 54:424-428. (Pubitemid 39177464)
2. Barlass PJ, Houston CW, Clements MO, Moir A. 2002. Germination of Bacillus cereus spores in response to L-analine and to inosine: the roles of gerL and gerQ operons. Microbiology 148:2089-2095. (Pubitemid 34785293)
3. Bast DJ, et al. 2004. Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J. Antimicrob. Chemother. 54:90-94. (Pubitemid 39028973)
4. Bergman NH, et al. 2006. Transcriptional profiling of the Bacillus anthracis life cycle in vitro and an implied model for regulation of spore formation. J. Bacteriol. 188:6092-6100. (Pubitemid 44448551)
5. Brook I, et al. 2001. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides, and quinolones. Int. J. Antimicrob. Agents 18:559-562. (Pubitemid 33152750)
6. Centers for Disease Control and Prevention. 2001. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb. Mortal. Wkly. Rep. 50:909-919.
7. Centers for Disease Control and Prevention. 2002. Evaluation of postexposure antibiotic prophylaxis to prevent anthrax.MMWRMorb. Mortal. Wkly. Rep. 51:59.
8. Clinical and Laboratory Standards Institute. 2006. Methods for dilutional antimicrobial susceptibility testing for bacteria that grow aerobically. Approved standard M7-A7, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Deziel MR, et al. 2005. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106. (Pubitemid 41778926)
10. Dixon TC, Meselson M, Guillemin J, Hanna PC. 1999. Anthrax. N. Engl. J. Med. 341:815-826. (Pubitemid 29420478)
11. Drusano GL, et al. 2009. Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 53:4718-4725.
12. Drusano GL, et al. 2008. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Antimicrob. Agents Chemother. 52:3973-3979.
13. Friedlander, AM, et al. 1993. Postexposure prophylaxis against experimental anthrax. J. Infect. Dis. 167:1239-1242.
14. Gold HS, Pillai SK. 2009. Antistaphylococcal agents. Infect. Dis. Clin. North Am. 23:99-131.
15. Heine HS, et al. 2007. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother. 51:1373-1379. (Pubitemid 46586819)
16. Hu H, Sa Q, Koehler TM, Aaronson AI, Zhou D. 2006. Inactivation of Bacillus anthracis spores in murine primary macrophages. Cell. Microbiol. 8:1634-1642. (Pubitemid 44350022)
17. Inglesby, T, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236 -2252.
18. Jernigan JA, et al. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944.
19. Kao LM, et al. 2006. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother. 50:3535-3542. (Pubitemid 44684862)
20. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim- sulfamethoxazole, and vancomycin against communityassociated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in a murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents Chemother. 52:2156-2162. (Pubitemid 351758553)
21. Louie A, et al. 2007. Efficacy of human, mouse, and humanized-mouse pharmacokinetic stimulations of ciprofloxacin against Yersinia pestis in an in vitro hollow fiber infection model, abstr. A-1432, p. 33. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
22. Louie A, et al. 2010. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob. Agents Chemother. 54:2646-2654.
23. Louie A, et al. 2008. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 52:2486-2496. (Pubitemid 351915680)
24. Louie A, Deziel MR, Liu W, Drusano GL. 2007. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrob. Agents Chemother. 51:2661-2667. (Pubitemid 47206197)
25. Louie A, et al. 2012. Differential effect of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob. Agents Chemother. 56:513-517.
26. Lyons CR, et al. 2004. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect. Immun. 72:4801-4809. (Pubitemid 38989340)
27. McKevitt MT, et al. 2007. Effects of endogenous D-alanine synthesis and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections. Infect. Immun. 75:5726-5734. (Pubitemid 350207810)
28. Mikesell P, Ivins BE, Ristroph JD, Dreier TM. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39:371-376. (Pubitemid 13212538)
29. Mock, M, Fouet A. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671. (Pubitemid 32978119)
30. Moir A. 2006. How do spores germinate? J. Appl. Microbiol. 101:526-530. (Pubitemid 44222283)
31. Moir A, Coref BM, Behravan J. 2002. Spore germination. Cell. Mol. Life Sci. 59:403-409. (Pubitemid 34267380)
32. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guidelines; document M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
33. PDR Staff. 2007. Physicians' desk reference. Thomson PDR, Montvale, NJ.
34. Roberts MC. 2003. Tetracycline therapy: update. Clin. Infect. Dis. 36:462-467. (Pubitemid 36241313)
35. Russell AD. 1982. The destruction of bacterial spores, p 30-77. Academic Press, New York, NY.
36. Shepard CW, et al. 2002. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg. Infect. Dis. 8:1124-1132. (Pubitemid 35257005)
37. Stevens DL, Bryant AE, Hackett SP. 1995. Antibiotic effects on bacterial viability, toxin production, and host response. Clin. Infect. Dis. 20(Suppl. 2):S154-S157.
38. Stevens DL, Gibbons AE, Bergstrom R, Winn V. 1988. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158:23-28.
39. Stevens DL, et al. 2007. Impact of antibiotics on expression of virulenceassociated exotoxin genes in methicillin-sensitive and methicillinresistant Staphylococcus aureus. J. Infect. Dis. 195:202-211. (Pubitemid 46080052)
40. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:3251-3255. (Pubitemid 28553749)
41. Thrupp, LD. 1986. Susceptibility of antibiotics in liquid media, p 93-150. In Lorian V (ed.), Antibiotics in laboratory medicine, 2nd ed. Williams & Wilkins, Baltimore, MD.
42. Weiss, et al. 2011. Antibiotics cure anthrax in animal models. Antimicrob. Agents Chemother. 55:1533-1542.
43. Worsham PL, Sowers MR. 1999. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can. J. Microbiol. 45:1-8.
44. Zimbelman J, Palmer A, Todd J. 1999. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr. Infect. Dis. J. 18:1096-1100.